Stocks in this list have an average analyst rating of either “Buy” or “Strong Buy”, and a price target that is at least 10% higher than the stock’s current price.
This list has performed -63.52% over the past year. By comparison, S&P 500 is 19.59% over the same period. This list includes 70.00% of Healthcare stocks, 10.00% of Utilities stocks, 10.00% of Technology stocks, 10.00% of Industrials stocks.
List performance is calculated using an equal-weight methodology. This list is generated by scanning the web and using our algorithms to surface potentially relevant securities to the topic. The list is intended to be educational and includes securities that may be suitable for a watchlist. It is not intended for investment or trading purposes. Microsoft does not recommend using the data and information provided as the basis for making any investment decision.
Read More : Giving Donald Trump a Pass at the GOP Debate
RENEW ENERGY GLOBAL PLC
RNW. ReNew Energy Global Plc is a United Kingdom-based company. The Company is a utility-scale renewable energy solutions providers in India. It operates wind, solar, and hydro energy projects. It provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services. It carries out business activities relating to the generation of power through non-conventional and renewable energy sources through ReNew Power Private Limited and its subsidiaries. It has primarily two reportable segments, namely wind power and solar power. Its wind power segment operates utility-scale wind energy projects in India and solar power segment operates its utility-scale and distributed solar energy projects in India. Other operations of the Company primarily include the sale of electricity from Hydro power and construction and maintenance of transmission lines. It offers a total commissioned capacity of 7.98 GW and an additional 5.72 GW of committed capacity.
This company’s number of analysts is 7.00, which makes it the 1st ranked stock in this list.
Renew Energy Global PLC. is -10.98% over the past month and -9.80% over the past year, underperforming the S&P 500 by -6.11% over the past month and -29.39% over the past year.
Read More : 5 Tips To Calm Your Nervous System When You’re Stressed
TEMPEST THERAPEUTICS, INC.
TPST. Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.
This company’s number of analysts is 4.00, which makes it the 2nd ranked stock in this list.
Tempest Therapeutics Inc. is -41.82% over the past month and -82.01% over the past year, underperforming the S&P 500 by -36.95% over the past month and -101.60% over the past year.
CYCLACEL PHARMACEUTICALS, INC.
Read More : 5 apps that can help with anxiety
CYCC. Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in solid tumors and hematological malignancies. The Company’s Mitosis Regulation program includes Plogosertib, which is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in acute leukemias and solid tumors.
This company’s number of analysts is 4.00, which makes it the 3rd ranked stock in this list.
Cyclacel Pharmaceuticals Inc. is -12.37% over the past month and -76.23% over the past year, underperforming the S&P 500 by -7.50% over the past month and -95.82% over the past year.
KAROOOOO LTD.
KARO. Karooooo Ltd. is a Singapore-based company, which is a provider of an on-the-ground operations cloud that maximizes the value of data. The Company operates through three segments: Cartrack, Carzuka, and Karooooo Logistics. Cartrack is a provider of an on-the-ground operational Internet of Things software-as-a-service (SaaS) cloud that maximizes the value of transportation, operation, and workflow data by providing insightful real-time data analytics to connected vehicles and equipment. Cartrack also includes systems integration, fleet administration, field worker management, video-based safety, risk mitigation, and delivery management. Carzuka is a physical and e-commerce vehicle buying and selling marketplace that allows customers to source, buy and sell vehicles. Karooooo Logistics provides a software application enabling the management of last-mile delivery and general operational logistics.
Read More : Watch how the iPhone 15 handles the bend test that busted the Pro Max
This company’s number of analysts is 4.00, which makes it the 4th ranked stock in this list.
Karooooo Ltd. is -17.69% over the past month and -16.30% over the past year, underperforming the S&P 500 by -12.82% over the past month and -35.89% over the past year.
CURIS, INC.
CRIS. Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The Company conducts its research and development programs both internally and through strategic collaborations.
This company’s number of analysts is 4.00, which makes it the 5th ranked stock in this list.
Curis Inc. is -41.08% over the past month and -52.93% over the past year, underperforming the S&P 500 by -36.20% over the past month and -72.52% over the past year.
